Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersanaâs lead product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and other cancers. In addition, multiple partners are using Mersanaâs platform to advance their ADC pipelines. Source
No articles found.
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed ...
EyePoint Pharmaceuticals, Inc. is a specialty b...
crooru is an on-demand, location-based app that connects health care staff and nur...
crooru is an on-demand, location-based app that...
Assertio Therapeutics is committed to providing responsible solutions to advance p...
Assertio Therapeutics is committed to providing...
Gamida Cell is a clinical-stage biopharmaceutical company committed to developing ...
Gamida Cell is a clinical-stage biopharmaceutic...
Join the National Investor Network and get the latest information with your interests in mind.